Lipum
5.85 SEK -4.88%Be the first to follow this company
Lipum is a biopharmaceutical company. The company is in the clinical phase and specializes in the discovery and development of new treatments for chronic inflammatory diseases. The company's drug candidate is based on an antibody intended to be used in treatments to block a specific molecule in the immune system. The drug candidate is in the clinical phase with preclinical data for rheumatism. The company is also evaluating other inflammatory diseases. Lipum has its operations in Umeå.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LIPUM
Daily low / high price
5.75 / 6.15
SEK
Market cap
124.09M SEK
Turnover
47K SEK
Volume
8.1K
Financial calendar
General meeting
2024-05-28
Interim report
2024-07-26
Interim report
2024-10-25
Annual report
2025-02-28
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 32.0 % | 32.0 % |
Försäkringsbolaget Avanza Pension | 12.0 % | 12.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Lipum AB: BioStock: Lipum's CEO looks ahead after the rights issue
Lipum offentliggör slutligt utfall i företrädesemissionen
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools